Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | The need to incorporate disease-modifying drugs in lower-risk MDS

Maria Diez Campelo, MD, PhD, University of Salamanca, University Hospital Salamanca, discusses the need to incorporate disease-modifying drugs in the treatment of patients with lower-risk myelodysplastic syndromes (LR-MDS) to improve their outcomes. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

5:27
Young matched unrelated donors versus older-aged matched sibling donors in alloSCT with PTCy
Karthik Nath • 17 Apr 2024
2:12
AlloSCT for AML with MDS-related features as per the ICC and WHO 2022 classifications
Arnon Nagler • 16 Apr 2024
1:17
The curative potential of alloSCT in the treatment of HR-MDS
Jurjen Versluis • 22 Apr 2024
2:22
Haplo-SCT for older patients with AML/HR-MDS: should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals